CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 2020—The U.S. Food and Drug Administration approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. Treatment with Palforzia (Aimmune Therapeutics) may be initiated in individuals ages four through 17 years with a confirmed diagnosis of peanut allergy and may be continued in individuals four years of age and older. Those who take Palforzia must continue to avoid peanuts in their diets.
Read More »